Supplementary Figure S2 from Bispecific Antibodies and Antibody–Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs
crossref（2023）
摘要
Proteasomal degradation inhibitors, Bortezomib and Lactacystin had little or no effect on PRLR turnover.
查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要